Algernon Pharmaceuticals (CSE: AGN – OTCQB: BTHCF) CEO Christopher Moreau joined Steve Darling from Proactive to share news the company has announced that Ifenprodil has reduced interleukin 6 with statistical significance in its recent Ifenprodil Phase 2b/3 COVID-19 trial. That is key information for the Company’s ongoing Phase 2 trial of Ifenprodil for idiopathic pulmonary fibrosis and chronic cough.
Speaking of that, the Company reports they have reached 50% of its enrolment target for its Phase 2 study Ifenprodil. The 20 patient proof-of-concept trial is to determine the efficacy of Ifenprodil in the preservation of lung function in IPF patients and associated chronic cough.